Address: Medialaan 40 bus 1 B-1800, Vilvoorde, Belgium
Tel: +32 2 246 16 11
Novartis in Belgium, with headquarters in Vilvoorde is a leading company for innovative medicines that improve the health maintain and improve well-being.
Approximately 1500 employees are to work in one of our four divisions: Novartis Pharmaceuticals, Sandoz and Novartis Consumer Health (OTC) and Alcon Eye Care (Alcon CIBA VISION +).
Novartis in Belgium is composed of the followoing departments:
– Novartis Pharma brings brand marketed drugs in 8 therapeutic areas: Cardiovascular and metabolic diseases, Hematology and Oncology, Central Nervous system, Respiratory Diseases, Infectious Diseases (IID) and Transplantation, Ophthalmology, Dermatology, bone diseases.
– Sandoz: is specialized in the production and sale of generic drugs.
– Novartis Consumer Health: is represented through the Novartis OTC business unit: OTC medications and self-medication products.
– Alcon Eye Care (Alcon CIBA VISION +): surgical and pharmaceutical products as well as eye care products.
Novartis is one of Belgian pharma’s biggest investors across manufacturing and R&D, contributing EUR 598.9 million to GDP in 2022, creating 4,403 direct and indirect jobs, and reaching 5,349,628 million…
Philippe de Pougnadoresse, country president & general manager pharma for Novartis Belgium & Luxembourg, outlines his affiliate’s fast and comprehensive response to the COVID-19 crisis, what can be learned from…
Mrs van der Kamp, you launched your career as a strategy consultant however, since then you have moved into the pharmaceutical industry by joining Novartis where you quickly worked your…
Back home in Belgium after a stellar stint in Big Pharma, Dr Paul Stoffels is now looking to reshape the future of cancer care with the previously struggling biotech he…
Belgian healthcare performs strongly across most metrics and international comparisons, but – as elsewhere – there remains room for improvement in terms of integrating patient feedback and experience into the…
20-year Astellas veteran Mark Dekker – now back in his home country of the Netherlands and overseeing the Benelux cluster having primarily developed his career in emerging European markets –…
Marnix Denys of beMedTech – the Belgian association for the medical technology industry – outlines the agenda priorities for the organisation that he hopes will lead to a more value-driven…
RaDiOrg aims to support rare disease patients and patient organisations in Belgium, defend their interests, and raise awareness of what can be devastating and little-understood conditions. Director Eva Schoeters –…
The newly merged Port of Antwerp-Bruges is the world’s first GDP-compliant seaport. CCO Tom Hautekiet explains the significant role the Port is playing in global healthcare supply chains – leveraging…
Back home in Belgium after a stellar stint in Big Pharma, Dr Paul Stoffels* is now looking to reshape the future of cancer care with the biotech he helped co-found…
Univercells is a group of companies founded a decade ago based around the concept of revolutionizing the availability of biologics around the world through making essential medicines affordable to all,…
GSK has undergone a number of changes in recent years. After driving a major transformation that began in 2017 to strengthen its R&D performance, the British multinational suffered the impact…
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has elected a new president and vice presidents who have set out a key priority for their term: a series of…
Vanja Hoeben oversees the Benelux cluster for South Africa-headquartered specialty and branded pharma firm Aspen. He describes the reorganisation that his organisation has undergone in the past few years, some…
Maria Fernanda Prado highlights some of the lessons drawn from her extensive experience in emerging markets which remain applicable in her current role as Janssen’s managing director for the Benelux…
See our Cookie Privacy Policy Here
